Survival Factors in Ovarian Cancer Surgery
Author Information
Author(s): Zang R Y, Harter P, Chi D S, Sehouli J, Jiang R, Tropé C G, Ayhan A, Cormio G, Xing Y, Wollschlaeger K M, Braicu E I, Rabbitt C A, Oksefjell H, Tian W J, Fotopoulou C, Pfisterer J, du Bois A, Berek J S
Primary Institution: Ovarian Cancer Program, Department of Gynecologic Oncology, Fudan University Cancer Hospital, Shanghai, China
Hypothesis
This study aims to identify prognostic factors and to develop a risk model predicting survival in patients undergoing secondary cytoreductive surgery for recurrent epithelial ovarian cancer.
Conclusion
The prognostic model may help predict survival benefits from secondary cytoreduction in patients with recurrent ovarian cancer.
Supporting Evidence
- Complete secondary cytoreductive surgery is linked to improved survival.
- Patients with no residual disease after surgery had a median survival of 57.7 months.
- The study included data from multiple international centers.
Takeaway
Doctors can use a new scoring system to figure out which ovarian cancer patients might live longer after surgery.
Methodology
Data from 1100 patients who underwent secondary cytoreductive surgery were pooled and analyzed to develop a risk model for survival.
Potential Biases
Selection bias may exist due to the nature of the surgical cohort.
Limitations
The study faced issues with missing data and did not include salvage chemotherapy as a prognostic factor.
Participant Demographics
The median age at recurrence was 56 years, with a range from 16 to 84 years.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI: 1.45–2.03
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website